Oncolytics Biotech Announces New Three-Arm Phase III Clinical Trial for Pelareorep in First-Line Pancreatic Cancer
Oncolytics Biotech Inc. has announced a new three-arm Phase III clinical trial for pelareorep in first-line pancreatic cancer. The trial will randomize patients to receive either standard chemotherapy or chemotherapy combined with pelareorep, with the primary endpoint being overall survival. The company plans to meet with the FDA in mid-November 2025 to discuss the study details. An interim efficacy analysis will be conducted during the trial. Results from this trial have not yet been presented.
Oncolytics Biotech Inc. has announced an update on the proposed design for its planned registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The trial will employ a three-arm design, randomizing patients to receive either gemcitabine plus nab-paclitaxel (GnP) as a control, GnP plus pelareorep, or GnP plus pelareorep with a checkpoint inhibitor. The primary endpoint of the study is overall survival. The company is scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to discuss further study details. Results from this trial have not yet been presented. The study design is informed by a post-hoc, pooled clinical analysis suggesting improved two-year survival rates with the addition of pelareorep to chemotherapy compared to chemotherapy alone. An interim efficacy analysis is planned to assess potential clinical benefit during the trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN85147) on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
